Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease

/PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases,...

Related Keywords

Berwyn ,Pennsylvania ,United States ,Marial Maccecchini ,Nic Johnson ,Cheng Fang ,Annovis Bio ,Exchange Commission ,Prnewswire Annovis Bio Inc ,Company Phase ,Research Development At Annovis Bio ,Drug Administration ,Annovis Bio Inc ,Russo Partners ,Novel Translational Inhibitor ,Multiple Neurotoxic Proteins ,Both Alzheimer ,Senior Vice President ,Annual Report ,Investor Contact ,